케미컬 필 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the chemical peel market size was valued at USD 1.23 billion in 2025 and is estimated to grow from USD 1.32 billion in 2026 to reach USD 1.99 billion by 2031, at a CAGR of 8.45% during the forecast period (2026-2031).

This report is Segmented by Product, Including Glycolic, Lactic, and More, by Peel Depth, Including Superficial, Medium, and Deep, by Application, Including Acne Spots and Post-Acne Marks, and More, by End Use, Including Dermatology Clinics, and More, and by Geography, Including North America, Europe, Asia-Pacific, MEA, and South America. The Market Forecasts are Provided in Terms of Value in USD.

Global Chemical Peel Market Trends and Insights

Rising Demand for Minimally Invasive Resurfacing

The sustained preference for low-downtime treatment is moving more patients toward superficial and medium-depth peels instead of more invasive resurfacing options. The AAFPRS 2025 Annual Survey, published in February 2026, stated that noninvasive procedures represent 80% of all facial procedures and also pointed to a 19% increase in facial procedure volume, which supports higher procedure flow across the chemical peel market. This shift matters because the procedure is easier to repeat, easier to fit into daily schedules, and easier for clinics to integrate into routine treatment menus. Demand is also getting younger, with patients under 30 choosing preventive care earlier, which extends the potential treatment cycle over more years. That pattern is pushing operators to build more repeat-visit protocols around light and medium treatments rather than relying on low-volume deep resurfacing alone.

Acne, Pigment, and Photoaging Case-Load Expansion

The chemical peel market continues to draw steady demand from acne, pigmentation, and photoaging case loads that remain large across both medical and aesthetic settings. Blue Shield of California stated in its February 2026 policy that acne vulgaris affects 80% of teenagers between 13 and 18 globally and that actinic keratosis affects 11% to 26% of the adult population in the United States, which supports durable baseline need for glycolic, salicylic, and TCA peels. The Federal Employee Program Medical Policy Manual from April 2025 also classified superficial 40% to 70% AHA peels as medically necessary for active acne unresponsive to systemic antibiotics and recognized dermal peels as medically necessary when more than 10 actinic keratoses are documented. That type of payer recognition reduces the usual price sensitivity seen in elective aesthetics and gives dermatology clinics a more predictable floor of demand. It also keeps chemical peels clinically relevant against newer topical options because the treatment can still deliver competitive outcomes at a lower procedural cost in many patient pathways.

Adverse-Event Risk in Medium and Deep Peels

Medium and deep peels still face a real adoption ceiling because adverse-event risk rises quickly when protocols are not handled by trained medical practitioners. Data presented at the AIME Congress in January 2026 stated that phenol-croton oil deep peels can deliver an average 8.2-year visual age reduction, but the face must be divided into aesthetic units and each application needs at least 15 minutes between sections to avoid cardiac arrhythmia risk. Those limits reduce throughput and keep the treatment concentrated in specialist dermatology and plastic surgery settings. They also make insurance, training, and legal exposure more difficult for mid-tier aesthetic clinics that want higher-margin treatments but lack the same depth of medical supervision. As a result, the chemical peel market continues to favor broad volume in superficial protocols while medium and deep peels remain narrower and more concentrated.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Assisted Skin Analysis and Protocol Personalization
2. Melanin-Safe Formulations Broaden Eligible Patients
3. FDA Scrutiny of Unsupervised High-Strength Home Peels

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Glycolic acid peel held 36.78% of the chemical peel market in 2025, which made it the largest product segment in the report. Its lead came from long clinical use across acne, photoaging, and hyperpigmentation, and from a penetration profile that practitioners understand well in daily treatment planning. That familiarity keeps glycolic acid in a strong first-line position across dermatology clinics and med spas because operators value protocol consistency as much as visible results. Salicylic acid maintains durable demand in acne care because of its lipophilic and comedolytic action, while TCA and phenol remain tied to specialist resurfacing use where deeper correction is needed. The chemical peel market still treats glycolic acid as the reference product because it sits at the center of both medical and aesthetic workflows, which gives it a reach that narrower specialty acids do not match.

Lactic acid peel is projected to grow at a 9.16% CAGR from 2026 to 2031, making it the fastest-growing product segment in the chemical peel market. Its appeal comes from a dual role in resurfacing and moisture support, which fits the growing preference for gentler protocols among patients with sensitivity concerns. That profile also aligns well with rising treatment demand from higher Fitzpatrick skin types, where tolerability matters more in first-time or maintenance care. Combination and fruit acid peels are the part of the chemical peel industry seeing the most active redesign, as brands use buffered systems and skin-mimetic carriers to improve tolerance and widen use across different skin types. As those systems improve recovery and comfort, they may pull some future demand away from single-acid formats before 2028.

Superficial or light peels retained 42.16% share of the chemical peel market size in 2025, supported by minimal downtime and broad compatibility across settings and skin types. They remain the default offer in beauty clinics and home-oriented routines because they are easier to repeat and carry a wider safety margin. Deep Peels stay concentrated in advanced dermatology and plastic surgery environments where cardiac monitoring, careful interval timing, and specialist training can be maintained. This creates a clear barbell structure in the chemical peel market, with high-volume superficial procedures at one end and low-volume high-revenue deep procedures at the other end. Medium Peels are filling the space between those two poles and are becoming the main value-growth layer through 2031.

Medium peels are projected to expand at an 8.83% CAGR from 2026 to 2031, making them the fastest-growing depth category in the chemical peel market. That pace reflects rising practitioner confidence in buffered TCA protocols and stronger comfort with medium-depth treatment for acne scarring and moderate photoaging. AIME Congress material presented in January 2026 also reinforced the clinical value of deeper resurfacing, which helps clinics justify selective upselling where training and patient screening are strong. AI-supported screening adds to this shift because it helps practitioners review contraindications more consistently before selecting a deeper procedure. The result is a broader middle tier in the chemical peel market where operators can move beyond basic resurfacing without taking on the full risk profile of deep phenol treatment.

Geography Analysis

North America accounted for 44.21% of the chemical peel market share in 2025, which made it the largest regional segment in the report. Demand remains high because the region has a dense network of dermatology clinics, med spas, and professional skincare brands that can support repeat treatment use. The AAFPRS 2025 Annual Survey published in February 2026 stated that noninvasive treatments represented 80% of all facial procedures and pointed to a 19% increase in facial procedure volume, which supports recurring peel demand across U.S. clinical and aesthetic settings. Canada and Mexico add support to regional volume, and Mexico is especially relevant in medium and deep procedures because its medical tourism offer provides lower treatment costs than many U.S. clinics.

Europe remained the second-largest regional block in the chemical peel market, and product design in the region is strongly shaped by EU Cosmetics Regulation (EC) No 1223/2009. The regulation limits glycolic acid to 10% in rinse-off products and 8% in leave-on products with a minimum pH of 3.5, while salicylic acid is capped at 2% in leave-on formats . These limits favor buffered and combination systems that rely on protocol design rather than one high-strength acid alone. Germany, France, the United Kingdom, Italy, and Spain account for most regional volume, and Germany's import dependence leaves part of the market more exposed to exchange-rate movement and supply disruption.

Asia-Pacific is forecast to expand at a 10.21% CAGR from 2026 to 2031, the fastest regional pace in the chemical peel market. The region benefits from South Korea's role as a formulation hub, China's closer links between cosmetic and medical service models, and India's expanding urban dermatology network. Melanin-safe protocol development matters strongly here because a large share of the addressable patient base falls within Fitzpatrick IV to VI skin types, which raises demand for pigment-safe brightening and resurfacing options, and VI Peel Precision + Peptides is one example of this direction. The Middle East and Africa add growth through affluent GCC demand and medical tourism flows into specialist aesthetic centers. South America also remains relevant because Brazil combines a large eligible patient pool with a mature aesthetic medicine ecosystem, which makes it the strongest structural market in the region for professional peel brands.

1. Allergan Aesthetics
2. Bella Medical Products
3. Circadia by Dr. Pugliese
4. Dermaceutic Laboratoire
5. Dermalogica
6. Dr. Dennis Gross Skincare
7. Fixderma India Pvt. Ltd.
8. IMAGE Skincare
9. Jan Marini Skin Research
10. L'Oreal
11. Mediderma
12. MedPeel
13. Merz Pharma
14. mesoestetic Pharma Group
15. NeoStrata Company
16. Obagi Medical
17. PCA SKIN
18. Pierre Fabre / Glytone
19. Santen Pharmaceuticals
20. VI Aesthetics / VI Peel

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Minimally Invasive Resurfacing
  • 4.2.2 Acne, Pigment, and Photoaging Case-Load Expansion
  • 4.2.3 Med Spa and Dermatology Network Expansion
  • 4.2.4 Buffered And Combination-Acid Product Innovation
  • 4.2.5 AI-Assisted Skin Analysis and Protocol Personalization
  • 4.2.6 Melanin-Safe Formulations Broaden Eligible Patients
• 4.3 Market Restraints
  • 4.3.1 Adverse-Event Risk in Medium and Deep Peels
  • 4.3.2 Competition from Laser, Microneedling, and IPL
  • 4.3.3 FDA Scrutiny of Unsupervised High-Strength Home Peels
  • 4.3.4 Training Variability and Imported-Input Margin Pressure
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product
  • 5.1.1 Glycolic Acid Peel
  • 5.1.2 Lactic Acid Peel
  • 5.1.3 Salicylic Acid Peel
  • 5.1.4 Trichloroacetic Acid Peel
  • 5.1.5 Phenol Peel
  • 5.1.6 Combination and Fruit Acid Peel
• 5.2 By Peel Depth / Type
  • 5.2.1 Superficial / Light Peel
  • 5.2.2 Medium Peel
  • 5.2.3 Deep Peel
• 5.3 By Application
  • 5.3.1 Acne Spots and Post-Acne Marks
  • 5.3.2 Hyperpigmentation and Melasma
  • 5.3.3 Fine Lines and Wrinkles
  • 5.3.4 Scars
  • 5.3.5 Dark Circles
  • 5.3.6 Skin Brightening and Tone Correction
• 5.4 By End Use
  • 5.4.1 Dermatology Clinics
  • 5.4.2 Med Spas
  • 5.4.3 Hospitals
  • 5.4.4 Beauty and Aesthetic Clinics
  • 5.4.5 Home Care Settings
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Allergan Aesthetics
  • 6.3.2 Bella Medical Products
  • 6.3.3 Circadia by Dr. Pugliese
  • 6.3.4 Dermaceutic Laboratoire
  • 6.3.5 Dermalogica
  • 6.3.6 Dr. Dennis Gross Skincare
  • 6.3.7 Fixderma India Pvt. Ltd.
  • 6.3.8 IMAGE Skincare
  • 6.3.9 Jan Marini Skin Research
  • 6.3.10 L'Oreal
  • 6.3.11 Mediderma
  • 6.3.12 MedPeel
  • 6.3.13 Merz Aesthetics
  • 6.3.14 mesoestetic Pharma Group
  • 6.3.15 NeoStrata Company
  • 6.3.16 Obagi Medical
  • 6.3.17 PCA SKIN
  • 6.3.18 Pierre Fabre / Glytone
  • 6.3.19 Santen Pharmaceutical Co., Ltd.
  • 6.3.20 VI Aesthetics / VI Peel

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment